According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Low-grade pediatric gliomas
Consideration of the tumor microenvironment opens up new treatment options
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Patient-centered rounds in medicine
Aligning care with the patient
- HIV: antiretroviral therapy (ART)
Single-tablet regimens support adherence
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Vaccinations against viral respiratory infections
Influenza, Covid-19 and RSV – Update 2025
- GLP1-RA therapy
Improvement in either weight or HbA1c – but never both
- Suicide